摘要
随着细菌耐药问题日益突出,颅内多重耐药(MDR)革兰阴性菌感染成为临床的棘手问题。近年上市的头孢他啶阿维巴坦(CAZ-AVI)对MDR革兰阴性菌显示出良好的抗菌活性,本文介绍了临床上8例CAZ-AVI治疗MDR革兰阴性菌颅内感染病例,除1例治疗失败外,其余7例均显示有效。CAZ-AVI有望成为临床治疗颅内革兰阴性菌感染的新选择。
With the growing trend of bacterial drug-resistance, intracranial infection caused by multidrug resistant(MDR) Gram-negative bacteria have become a difficult clinical problem. Ceftazidime-avibactam(CAZ-AVI), which has been marketed in recent years, shows good antibacterial activity against MDR Gram-negative bacteria. This paper presents 8 cases of intracranial infection caused by MDR Gram-negative bacteria which were treated by CAZ-AVI. Except one case failed, the other 7 cases were effective. CAZ-AVI is expected to become a new clinical option for the treatment of intracranial Gram-negative bacterial infections.
作者
潘晶晶
高峻
孟海阳
李莹
韩超
PAN Jing-jing;GAO Jun;MENG Hai-yang;LI Ying;HAN Chao(Ruzhou People's Hospital,Ruzhou HE-NAN 467599,China;Department of Pharmacy,the First Affiliated Hospital of Zhengzhou University,Zhengzhou HE-NAN 450052,China)
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2021年第2期86-90,共5页
Chinese Journal of New Drugs and Clinical Remedies
基金
河南省高等学校重点科研项目(19A360033)。
关键词
头孢他啶
阿维巴坦
革兰阴性菌感染
抗药性
细菌
ceftazidime
avibactam
Gram-negative bacterial infections
drug resistance
bacterial
